FDA
Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite assurances of swift reviews under the FDA’s new Commissioner’s National Priority Voucher program.
FEATURED STORIES
After a tumultuous year, experts call for stability while anticipating the first fruits of policies intended to expedite approvals for rare disease drugs.
The FDA’s announcement that it will phase out in vivo testing requirements for monoclonal antibodies marks a seismic shift. Here’s how industry can adapt.
Policy initiatives have come fast and furious at the FDA this year. While guidances on rare diseases and vaccines have consumed most of the ink, policy shifts aimed at improving FDA efficiencies and reshoring U.S. manufacturing also got some attention. Here, BioSpace rounds up more than a dozen initiatives relevant to the biopharma industry.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
CMV is a common and potentially serious viral infection in allogeneic HSCT recipients.
People diagnosed with the rare blood disorder known as Erdheim-Chester disease have a new treatment option.
EyeOP1 is an high-intensity focused ultrasound device that is the first non-invasive treatment for glaucoma in China.
Tianjin CanSino Biologics announced CFDA approval of its Ebola virus vaccine for China.
Alexion is set to secure even more revenue from its blockbuster drug Soliris, the most expensive drug in the world.
Big pharmas are having a good year so far in terms of FDA approvals.
A look at how the gene therapy approvals may end up confusing payers, lawmakers, and the general public at a time when the industry desperately needs clarity.
An advisory panel with the FDA gave a near unanimous support to Novo Nordisk’s diabetes drug semaglutide, a long-acting GLP-1 analogue.
Maybe timing is everything. On Aug. 28, 2017, Gilead acquired Kite for about $11.9B.
Officially, there have been four new chemical entities have been approved since our last issue.